Lupin Spins Out Two Oncology Programs into US-Based Kaveri Therapeutics
Lupin has spun out two oncology drug programs, LNP7457 (PRMT5) and LNP8701 (SOS1), into Kaveri Therapeutics, a US-based clinical-stage company. Lupin's wholly owned US subsidiary holds an 82.2% equity stake in Kaveri and provided seed funding. Kaveri will independently advance the programs through global clinical trials targeting solid tumors such as lung, pancreatic, ovarian, and CNS cancers, while seeking additional capital. Both programs have shown encouraging clinical progress with positive data presented at recent ASCO meetings.
First-hand measurement across 4 sources
We measured how 4 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is positive (68/100). Lens Score 42/100.
Outlets measured: thehindu, thetribune, businessstandard, businessstandard. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (68–70/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
businessstandard broke this story on 21 Jul, 04:06 am. Other outlets followed.